Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Plus Therapeutics Inc chart...

About the Company

plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.

$0M

Total Revenue

19

Employees

$8M

Market Capitalization

-0.70

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PSTV News

Plus Therapeutics Inc PSTV

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

13d ago, source: Stockhouse

AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

7d ago, source: Stockhouse

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript

11d ago, source: InvestingChannel on MSN

Q4 2023 Earnings Call March 5, 2024 Plus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.7, expectations ...

Plus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

13d ago, source: Finanznachrichten

The webcast will be available on the Company's website for 90 days following the live call. Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for ...

Q4 2023 Plus Therapeutics Inc Earnings Call

12d ago, source:

Sean Lee; Analyst; H.C. Wainwright & Co., LLC Edward Woo; Analyst; Ascendiant Capital Markets ...

Plus Therapeutics Inc PSTV

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript

2d ago, source: InvestingChannel on MSN

March 14, 2024 Allogene Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...

Plus Therapeutics Inc.

3y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PSTV Plus Therapeutics, Inc.

1mon ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...